Jason Lettmann joined Morgenthaler in 2009 and is a Partner on the Life Science Team. Jason invests in biopharmaceutical and medical device companies and brings over 15 years of operating and venture experience in the life science sector. Jason currently serves on the Board of Directors of FIRE1, Promedior, Ra Pharmaceuticals, Relievant Medsystems, Second Genome, Spinewave and Vapotherm. Jason also recently established Lightstone’s Europe office in Dublin, Ireland, to expand the firm’s investment activities to Europe.
Before joining Morgenthaler, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in medical devices and the life sciences. During his time at Split Rock, Jason was a board observer at Ardian (acquired by Medtronic in 2011) and Cabochon Aesthetics (acquired by Ulthera in 2014) as well as actively involved with the firm’s investments in Atritech (acquired by Boston Scientific), Entellus Medical (NASDAQ: ENTL), and Evalve (acquired by Abbott Labs). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013 as well as involved with the founding of Zyga Technologies.
Prior to Split Rock, Jason’s experience includes tenure with Guidant Corporation’s Compass Group which focused on corporate venture investing and business development, as well as a consultant with Accenture’s Health and Life Science practice where he advised clients across the medical device, pharmaceutical and health payer sectors. Jason also previously worked as a genetic research analyst at the University of Iowa Hospitals and Clinics.
Jason holds an M.B.A. with distinction from the University of Michigan’s Ross School of Business and a B.A. with honors from the University of Iowa.
- Ra Pharmaceuticals
- Relievant Medsystems
- Second Genome
Life Sciences/Medical Devices
- The Human Microbiome Gets A Big Pharma Investment
- Second Genome Closes Series A With $11.5M
- Vapotherm Closes $29 Mln Round
- Relievant Medsystems Announces $30 Million Series D Financing
- Relievant Medsystems Receives FDA Approval to Begin Pivotal Study
- Second Genome Raises $5M Series A To Map Microbes
- Second Genome Announces Series A Financing